Ashish Manne, Associate Professor at Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, shared a post on LinkedIn:
“We don’t often see breakthroughs like this in pancreatic cancer.
Daraxonrasib’s survival benefit is impressive – and, most importantly, represents meaningful hope for patients.
This has been a long journey in a disease where progress has often felt incremental at best. Moments like this matter – not just scientifically, but for what they mean to patients and families who have been waiting for better options.
Cautiously optimistic and looking forward to the fine print – but genuinely excited about what this could represent.”
Other articles featuring Ashish Manne.